# SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

> **NCT03732508** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Cancer

## Interventions

- **DRUG:** Irinotecan liposome
- **DRUG:** SHR-1316
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT03732508
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11
- **Primary completion:** 2019-11
- **Final completion:** 2020-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732508, "SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03732508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*